NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.72
-0.22 (-2.77%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.94
Open7.87
Bid7.70 x 1000
Ask7.71 x 4000
Day's Range7.63 - 7.94
52 Week Range3.54 - 43.40
Volume1,804,471
Avg. Volume4,246,313
Market Cap247.986M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-6.87
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.75
  • Drugmakers see long road ahead in coronavirus vaccine race
    Reuters Videos

    Drugmakers see long road ahead in coronavirus vaccine race

    Novavax is one of at least a dozen drugmakers racing to find a vaccine for the new Wuhan coronavirus. The Gaithersburg, Maryland - based company already has a vaccine in development against MERS - another type of coronavirus. But while reports of a supposed 'breakthrough' took financial markets out of their rut this week and sparked optimism that researchers could find an effective treatment, companies Reuters spoke to said not so fast - warning they have a long way to go to help those infected... ..from the outbreak of the flu-like virus that has killed more than 500 people in China and shows no signs of slowing down, with thousands of new cases reported each day. But Novavax research chief - Gregory Glenn - thinks the bio tech company is in a good position. "Novavax, has in the past gone from getting the gene sequence, identifying the virus to starting testing in 90 days for ebola and for a pandemic potential flu vaccine. So we've done it so everyone is very focused on trying to compress these time frames." Johnson & Johnson and Gilead Sciences are also rushing to develop treatments. And it's no easy feat, according to health experts, to move vaccines from the lab to widespread use in patients involves a number of hurdles. In addition to scaling up manufacturing capacity and building distribution networks, there are also regulatory hurdles that include carrying out large clinical trials. In a process that could push back a drug's release date by a year or more - according to executives from companies involved in the effort. And it's also pricey. Investment costs could run as high as $800 million for a vaccine that may or may not prove profitable. One analyst pointed out that by the time a vaccine is deemed safe, 'the outbreak could be abating."

  • These are the steps needed for a vaccine to be approved
    MarketWatch

    These are the steps needed for a vaccine to be approved

    Thirty countries and territories have confirmed cases of the illness, called COVID-19; despite the containment measures in place, the number is still on the rise, seemingly unfettered. As the outbreak claims more lives and the number of infected continues to grow, pharmaceutical companies, governments, universities and the World Health Organization are working around the clock to develop a vaccine. Once it is eventually developed, tested and administered, a vaccine will enable an individual’s immune system to effectively respond to the viral infection, preventing its propagation among the inoculated.

  • Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

    Novavax (NVAX) closed at $7.95 in the latest trading session, marking a -0.5% move from the prior day.

  • Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

    Is (NVAX) Outperforming Other Medical Stocks This Year?

  • Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $7.31, marking a +1.39% move from the previous day.

  • Can Biotech ETFs Continue to Soar in 2020?
    Zacks

    Can Biotech ETFs Continue to Soar in 2020?

    We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

  • Reuters

    FOCUS-Drugmakers see long road ahead in coronavirus vaccine race

    Drugmakers racing to find a vaccine or effective treatment for the deadly new coronavirus in China cautioned that they have a long way to go. At least a dozen drugmakers are working on vaccines or antivirals and other treatments to help those infected with the fast-spreading contagion. Investment costs for vaccines could run as high as $800 million in a process that, even if accelerated, will likely take more than a year until approval, according to executives from companies involved in the effort.

  • Health Stocks Riding High on Virus Claims Draw Short Sellers
    Bloomberg

    Health Stocks Riding High on Virus Claims Draw Short Sellers

    (Bloomberg) -- Short sellers are pouncing to bet against small-cap drugmakers and life sciences technology firms that have boosted their share prices by claiming to target the novel coronavirus.The rallies for companies like NanoViricides Inc, Novavax Inc. and Inovio Pharmaceuticals Inc. after they announced plans to help combat the deadly virus prompted significantly more short selling, signaling skepticism on Wall Street. Short bets against the trio and those against Co-Diagnostics Inc. are among the highest levels in the last year as shares popped.Novavax and Inovio, which were among the first to tout their plans to study drug candidates, have seen their initial rallies fade with gains now sitting at less than 20% from mid-January. With the hoopla slowly fading, more than 25% of Novavax shares available for trading are currently sold short, with about 14% of Inovio facing the same fate, data compiled by S3 Partners shows.The smaller, more volatile companies NanoViricides and Co-Diagnostics, which are up more than 145% each, have drawn even more scrutiny from shorts. Short interest as a percentage of float spiked to top 38% and 17%, respectively, from just 7% and 5.6% at the start of the year, S3 data show.“At this point we would be surprised if any of the R&D efforts that have been brought to light over the past week or two manifest into treatments effectively used to treat the current strain of coronavirus,” Jared Holz, a Jefferies health-care strategist in New York, wrote over the weekend.Claims to study medicines for problems like the coronavirus happen “every time an epidemic takes over,” Holz continued. He pointed out that some management teams look to boost their value by mentioning vaccine strategies, though he is broadly skeptical of “companies being able to monetize the coronavirus in any material way, if at all.”Vir Biotechnology Inc. is another name that has gained after announcing plans to develop a drug candidate for the Wuhan strain of the coronavirus. Shares erased some of their gains this week, falling about 20% in the last two days, as Wall Street weighed its potential and JPMorgan downgraded its rating to neutral from overweight.Vir Biotechnology short interest rose to 5% of shares available for trading, S3 data show, up from a November low of just 2.2%.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Steven Fromm, Kristine OwramFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
    Zacks

    Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Novavax, Inc. (NVAX).

  • Barrons.com

    Some Drugmakers Are Racing to Develop a Coronavirus Vaccine. Why Big Pharma Isn’t Rushing In.

    While responses to the coronavirus will take time, biotechs and Johnson & Johnson are developing platforms for future viral threats.

  • Coronavirus: How Fast to 100,000 Infected?
    Zacks

    Coronavirus: How Fast to 100,000 Infected?

    The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

  • Coronavirus: Epidemic or Pandemic?
    Zacks

    Coronavirus: Epidemic or Pandemic?

    The current geometric rate of transmission implies that over 100,000 people could be infected by early February.

  • Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
    MarketWatch

    Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports

    A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.

  • Will Coronavirus Propel This Vaccine Maker’s Stock Even Higher?
    TipRanks

    Will Coronavirus Propel This Vaccine Maker’s Stock Even Higher?

    Fears that China's outbreak of a new "coronavirus" shocked the stock market on Monday, sending the S&P 500 down 1.57% -- and slicing 1.89% off the Nasdaq. What's bad news for many companies, however, could be good news for one unprofitable medical specialist in particular: Novavax (NVAX).With its shares down 82% in 52 weeks, Novavax stock hasn't had much to recommend itself to investors in recent months. However, rising panic over the effects of China's coronavirus outbreak sent Novavax shares spiking sharply upwards -- and that's entirely understandable, even if it's not entirely reasonable, as Ladenburg Thalmann analyst Michael Higgins explained in a research note to clients.Over the weekend, China's National Health Commission revealed that the number of persons infected by the "2019-nCoV virus" has spiked from 2,025 to 2,794, a 38% one-day jump in infections. At least 80 people have died already, and 461 more patients are in critical condition. At this rate, by the end of this week, the number of infections could top 5,000, and deaths -- 150.Given these statistics, it's only natural investors would cast about in search of a company working to develop a cure, and Higgins admits that Novavax is one such company."Per our conversations with management, it's possible for the company to develop a 2019-nCov vaccine that is ready for manufacturing scale-up in 90 days," says Higgins. Problem is, regulatory requirements for "toxicity and stability studies" ... followed by animal studies ... followed by human testing, mean that we're still months and months away from Novavax coming up with any kind of an effective solution to the outbreak -- much less profiting from it.Fortunately, says Higgins, although coronavirus is what's driving Novavax stock right now, there are more realistic and timely catalysts for the stock becoming attractive than the current health scare out of China. Two weeks ago, the FDA granted "Fast Track Designation" on Novavax's Phase 3 treatment for more seasonal flu viruses, the "recombinant hemagglutinin (HA) protein nanoparticle flu vaccine" NanoFlu. While perhaps not as immediate a crisis as China's coronavirus, flu season in the U.S. routinely sees about 140,000 patients hospitalized, and as many as 8,200 lives lost (and more than twice that over the course of the full year), making the flu actually a bigger threat to health and safety -- and a bigger market for Novavax -- than the current crisis fixating investors.Clinical trial results for NanoFlu are due out in late March. Assuming all goes well, and NanoFlu goes into production in 2022 or 2023, Higgins foresees Novavax leaping from an annual revenue rate of about $11 million in 2019, to something closer to $1 billion in annual sales by 2027.This then -- the common flu, rather than the Chinese flu-like symptoms that left stocks stricken on Monday -- is the reason that Higgins believes Novavax stock is worth $27.50 a share, and a buy rating. And if Novavax comes up with a cure to the 2019-nCoV coronavirus in the meantime? That would just be icing on the cake.All in all, TipRanks reveals the vaccine maker as one drawing bullish attention on Wall Street. Out of 4 analysts tracked in the last 3 months, all 4 rate NVAX a "buy." Furthermore, the 12-month average price target stands tall at $17.38, marking over 140% upside potential from where the stock is currently trading. (See NVAX stock analysis at TipRanks)

  • Barrons.com

    3 Biotech Stocks Are Soaring Because Everyone Wants a Coronavirus Vaccine

    Shares of a handful of small and mid-sized biotechs that are working on vaccines for the Wuhan coronavirus are surging.

  • CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
    MarketWatch

    CDC officials say coronavirus is similar to SARS, no new U.S. cases reported

    At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.

  • Analyst: China's coronavirus victims 'probably 10 times' higher than reported
    Yahoo Finance

    Analyst: China's coronavirus victims 'probably 10 times' higher than reported

    As the number of patients stricken by China’s coronavirus continues to mount, at least one analyst believes the country’s reported casualty count might be far higher than Beijing has publicly admitted.

  • MarketWatch

    Vaccine, diagnostics stocks rise again on spreading coronavirus

    Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc. , up 42%; NanoViricides Inc. , up 29%; Allied Healthcare Products Inc. , up 22%; Inovio Pharmaceuticals Inc. , up 24%; and Novavax Inc. , up 13%. The Centers for Disease Control and Prevention said Sunday that there are now five confirmed cases in the U.S., all of whom had traveled to Wuhan, the city in China where the virus was first identified. Chinese health officials have said that more than 2,700 people have been sickened and at least 80 people died, according to The Wall Street Journal. Market concerns have sent global stocks and U.S. futures tumbling on Monday. The S&P 500 and the Dow Jones Industrial Average are both 1% over the last week.

  • RPT-With Wuhan virus genetic code in hand, scientists begin work on a vaccine
    Reuters

    RPT-With Wuhan virus genetic code in hand, scientists begin work on a vaccine

    CHICAGO/LONDON, Jan 24 (Reuters) - When a newly organised vaccine research group at the U.S. National Institutes of Health (NIH) met for the first time this week, its members had expected to be able to ease into their work. In just three months time, they likely will be testing the first of a number of potential experimental vaccines against the new SARS-like coronavirus that is spreading in China and beyond. "I told them, 'you are going to have your baptism of fire, folks'," Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases within NIH, said of his inaugural address to the group this week.

  • With Wuhan virus genetic code in hand, scientists begin work on a vaccine
    Reuters

    With Wuhan virus genetic code in hand, scientists begin work on a vaccine

    CHICAGO/LONDON, Jan 24 (Reuters) - When a newly organised vaccine research group at the U.S. National Institutes of Health (NIH) met for the first time this week, its members had expected to be able to ease into their work. In just three months time, they likely will be testing the first of a number of potential experimental vaccines against the new SARS-like coronavirus that is spreading in China and beyond. "I told them, 'you are going to have your baptism of fire, folks'," Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases within NIH, said of his inaugural address to the group this week.

  • Novavax exec: Making a coronavirus vaccine could take a long time
    Yahoo Finance

    Novavax exec: Making a coronavirus vaccine could take a long time

    The coronavirus that has killed dozens and rattled markets has no immediate cure — and a vaccine could be years in the making, a medical executive told Yahoo Finance.

  • ETF Trends

    Biotech ETFs Are Not Riding the Wave from Coronavirus Panic

    Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. Among the worst performing non-leveraged ETFs of Friday, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) declined 3.4% and SPDR S&P Biotech ETF (XBI) decreased 3.2%. Meanwhile, the more broadly watched  iShares Nasdaq Biotechnology ETF (IBB) fell 2.5%.